173 related articles for article (PubMed ID: 30260228)
1. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
[TBL] [Abstract][Full Text] [Related]
2. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
3. Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism.
Martinefski MR; Elguero B; Knott ME; Gonilski D; Tedesco L; Gurevich Messina JM; Pollak C; Arzt E; Monge ME
J Proteome Res; 2021 Jan; 20(1):786-803. PubMed ID: 33124415
[TBL] [Abstract][Full Text] [Related]
4. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-mass spectrometry based serum peptidomic approach for renal clear cell carcinoma diagnosis.
Huang Z; Zhang S; Hang W; Chen Y; Zheng J; Li W; Xing J; Zhang J; Zhu E; Yan X
J Pharm Biomed Anal; 2014 Nov; 100():175-183. PubMed ID: 25168216
[TBL] [Abstract][Full Text] [Related]
7. Exploring serum metabolic markers for the discrimination of ccRCC from renal angiomyolipoma by metabolomics.
Xiang M; Du F; Dai J; Chen L; Geng R; Huang H; Xie B
Biomark Med; 2020 Jun; 14(8):675-682. PubMed ID: 32613842
[No Abstract] [Full Text] [Related]
8. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison.
Leuthold P; Schaeffeler E; Winter S; Büttner F; Hofmann U; Mürdter TE; Rausch S; Sonntag D; Wahrheit J; Fend F; Hennenlotter J; Bedke J; Schwab M; Haag M
J Proteome Res; 2017 Feb; 16(2):933-944. PubMed ID: 27992229
[TBL] [Abstract][Full Text] [Related]
10. Coupled Mass-Spectrometry-Based Lipidomics Machine Learning Approach for Early Detection of Clear Cell Renal Cell Carcinoma.
Manzi M; Palazzo M; Knott ME; Beauseroy P; Yankilevich P; Giménez MI; Monge ME
J Proteome Res; 2021 Jan; 20(1):841-857. PubMed ID: 33207877
[TBL] [Abstract][Full Text] [Related]
11. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.
Yang J; Yang J; Gao Y; Zhao L; Liu L; Qin Y; Wang X; Song T; Huang C
PLoS One; 2014; 9(11):e111364. PubMed ID: 25368985
[TBL] [Abstract][Full Text] [Related]
13. Expression and significance of Cystatin-C in clear cell renal cell carcinoma.
Guo K; Chen Q; He X; Yao K; Li Z; Liu Z; Chen J; Liu Z; Guo C; Lu J; Wu C; Li W; Wang Q; Chen P; Lu W; Wang Y; Han H; Cao Y; Guo S
Biomed Pharmacother; 2018 Nov; 107():1237-1245. PubMed ID: 30257338
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
[TBL] [Abstract][Full Text] [Related]
15. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
[TBL] [Abstract][Full Text] [Related]
16. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry.
Wu N; Wang W; Yi M; Cheng S; Wang D
Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma.
Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G
Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793
[TBL] [Abstract][Full Text] [Related]
18. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic values of serum amino acid levels for clear cell renal cell carcinoma.
Zhang F; Ma X; Li H; Guo G; Li P; Li H; Gu L; Li X; Chen L; Zhang X
Urol Oncol; 2017 Jun; 35(6):392-400. PubMed ID: 28188089
[TBL] [Abstract][Full Text] [Related]
20. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma.
Lou N; Ruan AM; Qiu B; Bao L; Xu YC; Zhao Y; Sun RL; Zhang ST; Xu GH; Ruan HL; Yuan CF; Han WW; Shi HC; Yang HM; Zhang XP
Urol Oncol; 2017 Jan; 35(1):36.e7-36.e14. PubMed ID: 27633984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
